Celldex (CLDX) Tops Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Celldex (CLDX) Tops Q1 EPS by 3c

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

May 5, 2025 4:01 PM EDT

HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Companys ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken during screening demonstrate the presence of high numbers of intraepithelial mast cells in participants with active EoE and correlate with eosinophil counts, supporting the hypothesis that treating EoE with barzolvolimaba mast cell depleting agentcould provide promising therapeutic benefit. The data were discussed in a poster presentation at the Digestive Disease Week (DDW) 2025 conference in San Diego today. Celldex announced in February 2025 that enrollment to the Phase 2... More